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Aim To use the antioxidant compounds (sodium selenite, 
selenomethionine, D-pantethine) for modulation of cyto-
toxic effect of doxorubicin and cisplatin toward wild type 
and drug-resistant mutants of several human tumor cells. 
Similar treatments were applied in vivo toward adult male 
Wistar rats.
Methods Human tumor cells of different lines (HCT-116, 
Jurkat and HL-60) with various mechanisms of drug-resis-
tance were treated with doxorubicin or cisplatin, alone or 
in combination with sodium selenite, selenomethionine, 
or D-pantethine. Cell viability, induction of apoptosis, and 
production of O2
- radicals were measured. Activity of redox 
potential modulating enzymes was measured in the liver 
and blood plasma of adult male Wistar rats subjected to 
similar treatments.
Results All antioxidants used in physiologically harmless 
concentration inhibited cytotoxic action of doxorubicin 
toward tumor cells sensitive to chemotherapy treatment 
by 15%-30%, and slightly enhanced cytotoxic effect of this 
medicine toward drug-resistant malignant cells. At the 
same time, there was no significant effect of these antioxi-
dants on cisplatin action. Such effects were accompanied 
by a complete inhibition of production of superoxide radi-
cals induced by doxorubicin. The results of in vivo study in 
adult male Wistar rats were in agreement with the results 
of in vitro study of human tumor cells.
Conclusion Protective effect of specific antioxidant agents 
during cytotoxic action of doxorubicin was demonstrated 
in vitro in drug-sensitive human tumor cells and in adult 
male Wistar rats, while there was no protective effect in 
drug-resistant sub-lines of these tumor cells during action 
of doxorubicin and cisplatin.
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Low selectivity of action of the chemotherapeutic agents 
is one of their main shortcomings, leading to serious neg-
ative side effects in cancer patients. The main reason for 
this phenomenon is the formation of free radicals during 
the action of these drugs in both normal and tumor cells. 
Doxorubicin and cisplatin are among the most common-
ly used anticancer drugs. They realize the antineoplas-
tic activity by the intercalation into DNA structure and 
production of the reactive oxygen species (ROS) (1-3). 
However, these drugs lead to severe cardio- and neph-
rotoxicity, which significantly limits their use for tumor 
treatment (4). It was shown that side effects of doxorubi-
cin and cisplatin are mediated by hydroxyl radicals, which 
are formed in the presence of iron (II) from superoxide 
anions whose production is induced by these drugs (3,5). 
Numerous studies indicate that ROS-induced apoptosis 
of tumor cells takes place only under supraclinical dos-
es of anthracyclines, and ROS production is not critical 
for realization of their anticancer activity (3). Thus, selec-
tive blocking of ROS action by specific antioxidant agents 
should at least partially reduce the toxicity of doxorubicin 
and cisplatin toward normal cells, without significant im-
pact on the antitumor action of these drugs. Promising 
candidates for such role are derivatives of the pantoth-
enic acid, since they possess significant antioxidant effect 
toward the mammalian cells and are able to protect the 
cells against toxic effects of free radicals (6). The inorgan-
ic and organic selenium derivatives (sodium selenite and 
selenomethionine) belong to another group of antioxi-
dants that demonstrated a protective effect during cis-
platin chemotherapy (7,8). Similar protective effects were 
also observed for the pantothenic acid (9). However, it re-
mains unknown whether these antioxidants are capable 
of inhibiting the production of harmful ROS (including 
superoxide and hydroxyl radicals) due to the action of an-
ticancer agents, and at the same time not interfering with 
the anti-tumor activity of these drugs. Besides, the effect 
of D-pantethine, selenomethionine, and sodium selenite 
used in combination with the anticancer drugs toward 
tumor cells resistant to chemotherapy has not been stud-
ied thoroughly (10).
In this study, we aimed to develop new approaches for 
cancer chemotherapy that would eliminate negative side 
effects of the anticancer drugs caused by an excessive 
production of free radicals, which adversely affect nor-
mal tissues and organs in cancer patients. A chemother-
apy regimen based on a combination of specific antioxi-
dants (sodium selenite, selenomethionine, D-pantethine) 
and conventional anticancer drugs (doxorubicin, cisplatin), 
which are known to induce production of ROS, has been 
proposed. We studied the molecular mechanisms of anti-
tumor activity of doxorubicin and cisplatin combined with 
the antioxidants toward tumor cell lines possessing differ-
ent mechanisms of drug resistance. The results obtained in 
the in vitro study have been verified in experimental ani-
mals (rats).
MAteRiALS ANd MetHOdS
The study was conducted at the Institute of Cancer Re-
search Vienna, Austria, the Institute of Cell Biology, Lviv, 
Ukraine, and the Center of Food, National Academy of 
Sciences of Belarus in Grodno in 2013. Human isogen-
ic p53-null (p53−/−), Bax-null (Bax−/−), and wild-type 
(p53+/+, Bax +/+) human HCT-116 colon carcinoma cells 
(kindly provided by Dr Bert Vogelstein), human breast ad-
enocarcinoma cells of MCF-7 line, human T-leukemia cells 
of Jurkat line, human leukemia cells of HL-60 line, and its 
drug-resistant HL-60/vinc sub-line (overexpression of P-
glycoprotein) were obtained from cell culture collection 
at the Vienna Medical University, Institute of Cancer Re-
search. Cells were cultured in RPMI-1640 medium, sup-
plemented with 10% fetal calf serum (Sigma Chemical 
Co., St. Louis, MO, USA), 50 µg/mL streptomycin (Sigma 
Chemical Co.), and 50 units/mL penicillin (Sigma Chemi-
cal Co.) in 5% CO
2-containing humidified atmosphere at 
37°C. Cells were seeded into 24-well tissue culture plates 
(Greiner Bio-one, Frickenhausen, Germany). Short-term 
(24 hours) cytotoxic effect of anticancer drugs was stud-
ied under the Evolution 300 Trino microscope (Delta Op-
tical, Mińsk Mazowiecki, Poland) after cell staining with 
Trypan blue (0.1%).
To analyze cytotoxic activity of conventional anticancer 
drugs together with non-toxic doses of the antioxidants 
in vitro, tumor cell lines possessing various mechanisms of 
resistance to anticancer drugs were studied. For estimat-
ing the impact of the antioxidants on cytotoxic activity of 
conventional anticancer drugs, semi-lethal doses of cispla-
tin and doxorubicin causing death of 50% of malignant cell 
were used in combination with non-toxic doses of the an-
tioxidants. The effect of antioxidants that led to a 5%-10% 
(statistically unreliable) decrease in cytotoxic activity of 
drugs was considered weak, the effect that led to a decrease 
of 15%-30% was considered moderate, and that which led 
to a decrease of 30%-50% was considered strong.
The cells were stained with DAPI (4’,6-diamidino-2-
phenylindole) (Sigma) for studying chromatin con-
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densation in the MCF-7 cells treated with doxorubicin 
and antioxidants. 24 hours after the addition of drugs, 
MCF-7 cells were washed twice with 1x PBS, fixed for 15 
minutes at room temperature in 4% solution of paraform-
aldehyde, and permeabilized for 3 minutes with 0.1% Tri-
ton X-100 in the phosphate buffer saline (PBS). After that, 
cells were incubated for 5 minutes with 1 µg/mL solution 
of DAPI (Sigma), washed twice with PBS, and cover glass-
es with fixed cells were placed on slides. Cytomorpholog-
ical study was performed under Carl Zeiss AxioImager A1 
fluorescent microscope (Carl Zeiss, Göttingen, Germany).
The content of the ROS was measured after incubation of 
control or drug-treated (24 hours) MCF-7 cells with fluores-
cent dye dihydroethidum (DHE, O2
--specific) used in 10 μM 
concentration for 30 minutes at 37°C. After incubation with 
fluorochrome, cover glasses with cells were washed with 
PBS and placed on slides, and the intensity of fluorescence 
was immediately analyzed under Carl Zeiss AxioImager A1 
fluorescent microscope (Carl Zeiss).
Thirty-two adult male Wistar CRL rats with 90-110 g 
weight were kept under standard vivarium conditions 
with constant access to the full feed and drinking water. 
Animals were divided into 4 groups of 8 rats each. Rats 
from experimental groups were intragastrically adminis-
tered D-pantethine 400 mg/kg (group 3) and selenom-
ethionine 200 µ/kg (group 4) for 5 days. Rats from the 
first (control) group were injected simultaneously with 
equivalent volume of 0.9% sodium chloride solution in a 
similar mode. Doxorubicin (5 mg/kg) was injected once 
i.p. to the animals from 2-4th groups in 3 days before de-
capitation.
All in vivo experiments were conducted in accordance 
with the international principles of the European Conven-
tion for protection of vertebrate animals under a control of 
the Bio-Ethics Committee of the Center of Food, National 
Academy of Sciences of Belarus in Grodno.
The activity of glutathione reductase and glutathione 
transferase was measured according to Carlberg et al 
(11,12). Glutathione and its redox potential in erythrocytes 
was determined as previously described (13). Products that 
react with N, N-dimethyl-p-phenylenediamine in plasma 
were detected as previously described (14). Analysis of free 
SH-groups in proteins from blood plasma was done as pre-
viously described (15).
FiGuRe 1. Sodium selenite, selenomethionine, and d-pantethine decrease cytotoxic action of doxorubicin toward wild-type HCt-
116 cells, but have no impact on doxorubicin action toward HCt-116/Bax(−/−) and HCt-116/p53(−/−) sub-lines lacking Bax and p53 
genes. Medium – blank control (appropriate volume of culture medium added instead of the antioxidants). *P < 0.05 relative to the 
control. A – P = 0.0098, B – P = 0.0211, C – P = 0.0321.
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Activity of succinate dehydrogenase and 2-oxoglutarate 
dehydrogenase was measured spectrophotometrical-
ly (16). Sorption reaction with Nile blue dye was used as 
a functional test of the biological stability of erythrocyte 
membranes, as previously described (17). The level of ad-
sorption in erythrocytes was measured by using methyl-
ene blue assay (18).
Identification of coenzyme A (CoA) fractions was con-
ducted as previously described (19,20). The content of 
free form of CoA (CoA-SH) and short chain acyl-CoA de-
rivative (acetyl- CoA) in the rat liver was determined us-
ing HPLC assay on a HPLC instrument Agilent 1100/1200 
(Agilent Technologies, Santa Clara, CA, USA). Homogeni-
zation of liver tissue samples was performed at 4°C using 
4% HClO4 at a ratio of 1:6. The homogenates were centri-
fuged at 16 000 g for 15 minutes at 4°C and the obtained 
chlorine supernatants were adjusted to pH 5 with 20% 
NaOH. Prior to introduction into the chromatograph, the 
supernatant was filtered through a RC 0.45 μm, 13 mm fil-
ter (Agilent Technologies). Chromatographic column Zor-
bax SB-C18 150x3 mm, particle size 3.5 µm (Agilent Tech-
nologies) was used for HPLC.
All experiments were performed in triplicate and re-
peated 3 times. For statistical analysis, standard variation 
data within a group were calculated together with a sta-
tistical reliability of differences between two groups of 
data assessed by t-test. The level of significance was set 
to 0.05.
ReSuLtS
differential effect of antioxidants toward cytotoxic 
action of doxorubicin in drug-sensitive and drug-
resistant tumor cell lines
Human colon carcinoma cells of HCT-116 wild-type line 
(with intact copies of the p53 and Bax genes) and its sub-
lines HCT-116 (Bax (−/−) and HCT-116/p53 (−/−) char-
acterized by a knockout of Bax and p53 genes, respec-
tively, were chosen as an experimental model. Deletion 
of Bax gene resulted in a 2-fold increase in the resistance 
of these cells to doxorubicin action, whereas a deletion 
of the p53 gene did not affect this parameter (Figure 1). 
Sensitivity to sodium selenite and selenomethionine in 
HCT-116 wild-type cells and its gene knockout HCT-116/
FiGuRe 2. Sodium selenite, selenomethionine, and d-pantethine decrease cytotoxic action of doxorubicin toward human leukemia 
cells of Jurkat line and HL-60 line, but have no impact on doxorubicin action toward vincristin-resistant HL-60/vinc sub-line overex-
pressing P-glycoprotein. Medium – blank control (appropriate volume of culture medium added instead of antioxidants). *P < 0.05 
relative to the control, **P < 0.01 relative to the control. A – P = 0.010, B – P = 0.034, C – P = 0.002, e – P = 0.004, F – P = 0.026.
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p53 (−/−) and HCT-116/Bax (−/−) sub-lines was almost 
identical. These compounds used in 0.1-0.25 µM doses 
were completely non-toxic toward the studied cell lines 
(Figure 1). All applied antioxidants demonstrated moder-
ate cytoprotective action, decreasing by 15%-20% the cy-
totoxic effect of doxorubicin toward HCT-116 cells (Figure 
1). On the contrary, sodium selenite and selenomethion-
ine in the same dose (0.1 µM) did not protect HCT-116/
Bax (−/−) and HCT-116/p53 (−/−) sub-lines, while in a 
higher and still non-toxic concentration (0.25 µM) they 
only slightly intensified doxorubicin action (Figure 1). Sur-
prisingly, HCT-116/p53 (−/−) cells were hypersensitive to 
D-pantethine action, and thus 20 times lower concen-
trations of this antioxidant (1 µM and 2.5 µM) were used 
compared to doses applied toward wild-type cells (25 
µM and 50 µM, respectively). However, even in these low 
doses, D-pantethine did not act cytoprotectively toward 
HCT-116/p53 (−/−) and HCT-116/Bax (−/−) cells, while it 
protected HCT-116/wt cells with the same or even higher 
efficiency than did the selenium derivatives. Thus, antiox-
idants seem to protect against toxic effect of doxorubicin 
only drug-sensitive tumor cells, and have no impact on 
cytotoxic action of doxorubicin toward tumor cells with 
impaired structure of Bax and p53 genes.
In order to confirm the obtained results, human leukemia 
cells of HL-60 line and its drug-resistant HL-60/vinc sub-
line characterized by an overexpression of P-glycoprotein, 
were used. HL-60 cells are very sensitive to doxorubicin 
action (LC50 = 0.5 µM), and sodium selenite, selenomethi-
onine, and D-pantethine demonstrated weak protective 
effect against the action of this anticancer drug (Figure 
2). In contrast, the cells of HL-60/vinc sub-line showed a 
10-fold increase in their resistance to doxorubicin, while 
all applied antioxidants failed to have a protective effect 
in these cells (Figure 2). Human T-leukemia cells of Jur-
kat line were most sensitive to doxorubicin action, and 
they also responded distinctly on the protective action 
of sodium selenite, selenomethionine, and D-pantethine 
(Figure 2). In particular, sodium selenite in 0.05 µM dose 
or D-pantethine in 25 µM dose acting together with dox-
orubicin in its LC50 dose (0.5 µM) toward Jurkat T-cells 
significantly recovered the cell population to 78%-80% 
of the control level, while the effect of selenomethion-
FiGuRe 3. Sodium selenite, selenomethionine, and d-pantethine have no impact on viability of human leukemia cells of Jurkat line, 
HL-60 line, and its vincristin-resistant HL-60/vinc sub-line, overexpressing P-glycoprotein under cytotoxic action of cisplatin. Medium 
– blank control (appropriate volume of culture medium added instead of antioxidants).
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ine was slightly weaker. It should be noted that similar 
to HCT-116 cells, a slight increase (from 0.05 to 0.1 µM) in 
the concentration of these antioxidants decreased their 
cytoprotective effect (Figure 2).
Cytotoxic action of cisplatin is not affected in tumor 
cells by the antioxidants
In contrast to doxorubicin action, there was no cytoprotec-
tive effect of the antioxidants in the case of cisplatin action. 
A combined treatment of Jurkat T-leukemia cells with LC50 
dose of cisplatin (10 µM) and 0.1 µM of sodium selenite led 
to only a 4% decrease in cisplatin cytotoxicity, while sele-
nomethionine and D-pantethine had no effect at all (Fig-
ure 3). The same lack of effect was observed in the case 
of HL-60 leukemia cells, as well as its drug-resistant HL-60/
vinc sub-line (Figure 3). There was only a weak cytoprotec-
tive effect of sodium selenite of 7%, and a lack of effect of 
selenomethionine and D-panthenine toward cisplatin cy-
totoxic action in the parental HCT-116 cell line, as well as 
its drug-resistant Bax (−/−) and p53 (−/−) sub-lines (Figure 
4). Thus, drug-resistant tumor cells compared with drug-
sensitive tumor cells showed much weaker sensitivity to 
cisplatin action, which is similar to a decreased sensitivity 
to antioxidants’ action in the case of doxorubicin.
Antioxidants inhibit ROS production and apoptosis 
induced by doxorubicin in tumor cells
Sodium selenite, selenomethionine, and D-pantethine 
only partially (15%-30%) suppressed cytotoxic activity 
of doxorubicin in drug-sensitive tumor cells (Figure 1,2). 
Since ROS production is a supplementary pathway in 
apoptosis induced by doxorubicin (3), it is obvious that 
the observed effect of antioxidants is explained by the 
inhibition of production of superoxide anions under the 
doxorubicin treatment.
Next, we attempted to confirm the results obtained at the 
molecular level by studying the production of the super-
oxide radicals in human breast adenocarcinoma cells of 
MCF-7 line under the action of doxorubicin and the anti-
oxidants (Figure 5A). Doxorubicin (1 µM) caused a 10-fold 
increase in the production of superoxide anion compared 
FiGuRe 4. Sodium selenite, selenomethionine, and d-pantethine have no impact on viability of HCt-116 cells and their HCt-116/
Bax(−/−) and HCt-116/p53(−/−) sub-lines lacking Bax and p53 genes under cytotoxic action of cisplatin. Medium – blank control (ap-
propriate volume of culture medium added instead of antioxidants). * P < 0.05 relative to the control. A – P = 0.035.
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to control (untreated cells), whereas addition of sodium 
selenite (0.1 µM) reduced ROS production to nearly base-
line level. Selenomethionine (0.1 µM) and D-pantethine 
(25 µM) showed weaker but also pronounced inhibitory 
effect on ROS levels in MCF-7 cells (Figure 5A). Therefore, 
all applied antioxidants acted by inhibiting the production 
of superoxide anion in target tumor cells.
It is known that ROS are involved in the induction and 
regulation of apoptosis signaling pathways in various (in-
cluding tumor) cells (21,22). To ensure that antioxidants’ 
inhibition of production of superoxide anions induced by 
doxorubicin can also lead to further suppression of apop-
tosis, cytomorphological study of human breast adenocar-
cinoma cells of MCF-7 line under the action of doxorubicin 
in combination with the antioxidants was performed (Fig-
ure 5B). Doxorubicin (1 µM) caused a development of typi-
cal apoptosis hallmarks – hypercondensation of nuclear 
chromatin and cell contraction, whereas sodium selenite 
almost completely restored the cytomorphological phe-
notype of MCF-7 cells to normal. Selenomethionine and 
D-pantethine demonstrated similar effect (Figure 5B). Thus, 
inhibition of doxorubicin-induced production of toxic su-
peroxide anions under action of applied antioxidants also 
stopped the switching of apoptosis by this drug.
d-pantethine and selenomethionine inhibit oxidative 
stress induced in rat erythrocytes by doxorubicin action 
in vivo
Finally, we tried to confirm our conclusions from the treat-
ment of tumor cells in vitro in an animal study on adult 
male Wistar rats. A redox-status of experimental animals 
and redox efficiency of applied compounds were evalu-
ated by biochemical assays for analysis of glutathione sys-
tem in rat erythrocytes. Nile blue sorption and methylene 
tABLe 1. Glutathione level and its redox potential in erythrocytes of Wistar rats with combined administration of doxorubicin (dx), 
d-pantethine, and selenomethionine (SeMet) (mean ± standard deviation, n = 8)
Parameter Control dx d-panthetine +dx SeMet+dx
Reduced glutathione, µM/gHb 4.55 ± 0.40 4.33 ± 0.40 4.95 ± 0.43† 4.84 ± 0.50†
Oxidized glutathione, µM/gHb 0.057 ± 0.006 0.091 ± 0.004* 0.073 ± 0.009* 0.073 ± 0.007*
Redox ratio of reduced and oxidized glutathione 80.3 ± 5.8 51.0 ± 4.8* 67.7 ± 3.9*† 68.08 ± 4.62*†
Overall glutathione, µM/gHb 4.66 ± 0.41 4.51 ± 0.39 5.09 ± 0.44* 4.98 ± 0.28
Redox potential, mV -327.5 ± 3.3 -320.7 ± 3.5* -326.4 ± 3.0† -325.9 ± 3.1†
*P < 0.05 relative to the control.
†P < 0.05 relative to dx.
tABLe 2. indicators of Nile blue (NB) and methylene blue (MB) dye sorption in erythrocytes of Wistar rats with combined administra-
tion of doxorubicin (dx), d-pantethine, and selenomethionine (SeMet) (mean ± standard deviation, n = 8)
Parameter Control dx d-panthetine +dx SeMet+dx
Sorption coefficient (NB), conventional units (c.u.) 39.37 ± 3.32 43.86 ± 3.66* 42.62 ± 4.42 38.53 ± 5.43
Sorption coefficient (MB), c.u. 8.80 ± 0.69 9.87 ± 0.95 9.28 ± 0.99 9.21 ± 1.17
Sorption coefficient (NB), c.u./gHb 132.1 ± 8.9 141.2 ± 17.0 132.8 ± 17.5 127.7 ± 13.4
Sorption coefficient (MB), c.u./gHb 29.6 ± 3.1 31.8 ± 4.5 28.8 ± 3.3 30.7 ± 4.0
Absorption ratio (NB), % 84.8 ± 1.1 86.2 ± 1.0* 85.8 ± 1.4 84.4 ± 1.9
Absorption ratio (MB), % 74.5 ± 1.5 76.6 ± 1.8 75.4 ± 2.0 75.2 ± 2.3
*P < 0.05 relative to the control.
tABLe 3. Changes in oxidative stress indices in the blood plasma of Wistar rats under combined administration of doxorubicin (dx), 
d-pantethine, and selenomethionine (SeMet) (mean ± standard deviation, n = 8)
N,N-dimethyl-p-phenylenediamine Protein sulfhydryl-groups
conventional units /mL of blood plasma µM/mL of blood plasma µM/mg of protein
Control 397.5 ± 13.1 131.4 ± 9.5 1.66 ± 0.10
Dx 5 mg/kg 455.3 ± 27.6* 129.0 ± 9.1 1.68 ± 0.16
D-pantethine +Dx 393.4 ± 24.1† 105.2 ± 7.9*† 1.21 ± 0.11*†
SeMet+Dx 332.9 ± 26.9† 121.9 ± 5.9 1.49 ± 0.16*
*P < 0.05 relative to the control.
†P < 0.05 relative to dx.
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blue adsorption were applied for estimation of plasma 
membrane damage of erythrocytes under the doxorubi-
cin action. Doxorubicin treatment led to a decrease in the 
redox-potential of the erythrocytes, and it also sharply de-
creased GSH/GSSG ratio, while selenomethionine and D-
pantethine rapidly restored both parameters almost to the 
control level (Table 1). Doxorubicin caused a small dam-
age to plasma membranes of erythrocytes, as detected by 
Nile blue sorption (Table 2), but this damage was partial-
ly restored under the action of selenomethionine and D-
pantethine (Table 2). Doxorubicin also induced oxidative 
stress (measured by an increase in the level of diphenyl-
aminoreaсting substances), which was eliminated by a 
simultaneous application of D-pantethine or selenome-
thionine (Table 3). Total (effective) redox potential in the 
erythrocytes was rapidly decreased under doxorubicin ac-
tion, while selenomethionine totally blocked such action 
(Table 1). Surprisingly, a combined action of doxorubicin 
with D-pantethine led to a sharp decrease in the amount 
of protein sulfhydryl groups in blood plasma of treated rats 
(Table 3).
Multidirectional effects of d-pantethine and 
selenomethionine toward succinate dehydrogenase 
activity and coenzyme A content in the rat liver under 
doxorubicin action
In order to verify the involvement of mitochondrial oxida-
tion processes in realization of toxic effect of doxorubicin, 
succinate dehydrogenase (SDH) activity in the liver of ex-
perimental animals was studied (Figure 6). A 2.5-fold de-
crease in the activity of this enzyme was detected under 
the action of doxorubicin, while D-pantethine restored it 
to control level. In contrast, there was no significant effect 
of selenomethionine on the SDH activity (Figure 6).
The content and ratio of CoA fractions are considered to be 
essential indicators of the enzymatic systems involved in 
energy metabolism and detoxification processes. Doxoru-
bicin treatment led to a pronounced and significant drop 
in the fraction of free CoA, as well as of acid-soluble CoA in 
the rat liver tissue (Table 4). D-pantethine (CoA precursor) 
did not show any protective effect, whereas selenomethio-
nine showed a trend toward normalization of the studied 
parameters (Table 4). Since these data were obtained by 
FiGuRe 5. Sodium selenite, selenomethionine, and d-
pantethine inhibit production of superoxide anions (A) and 
induction of apoptosis (B) in human breast adenocarcinoma 
cells of MCF-7 line under doxorubicin treatment. 1 – control; 
2 – doxorubicin, 1 µM; 3 – doxorubicin, 1 µM+Na2SeO3, 0.1 µM; 
4 – doxorubicin, 1 µM+selenomethionine, 0.1 µM; 5 – doxoru-
bicin, 1 µM+d-pantethine, 25 µM.
tABLe 4. effect of intragastric administration of d-pantethine 
and selenomethionine (SeMet) on the contents of coenzyme A 
fractions (nmol/g of tissue) in the liver of rats under doxoru-
bicin (dx) treatment (CoA – coenzyme A) (mean ± standard 




acyls of CоА Free CоА
Control 292 ± 13 140 ± 9 152 ± 8
Doxorubicin 246 ± 12* 129 ± 7 117 ± 5*
D-pantethine+Dx 258 ± 14 136 ± 8 122 ± 6*
SeMet+Dx 262 ± 14 131 ± 7 131 ± 7
*P < 0.05 relative to the control.
FiGuRe 6. d-pantethine, but not selenomethionine, restores 
the activity of succinate dehydrogenase (SdH) (nmol/mg 
protein* min) in the rat liver under doxorubicin treatment. 
*P < 0.05 relative to the control, triangle represents P < 0.05 
relative to doxorubicin.
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using cyclic phosphotransacetylase assay, they cannot ex-
clude a direct effect of doxorubicin in that analytical sys-
tem. To avoid this problem, HPLC study of the content of 
free form of CoA (CoA-SH) and a short-chain acyl-CoA de-
rivative (acetyl-CoA) in the rat liver was carried out. The ob-
tained results confirmed the CoA-mediated mechanism of 
cytotoxic action of doxorubicin and demonstrated highly 
protective effect of the D-pantethine and selenomethion-
ine, which restored a quantity of both CoA-SH and acetyl-
CoA to the control level (Figure 7).
diSCuSSiON
Cardio- and nephrotoxicity of doxorubicin significantly 
limit its application in cancer chemotherapy. These neg-
ative side effects are caused by an excessive production 
of superoxide anions in the mitochondria of cells treated 
with doxorubicin (4). While the antitumor activity of this 
antibiotic is mainly implemented via inhibition of the DNA 
topoisomerase II (3), the induction of ROS is only a sup-
plementary, and, at the same time, harmful mechanism 
accompanying doxorubicin action toward target cells, 
particularly those which contain a large number of mi-
tochondria – cardiomyocytes and hepatocytes. This is 
why a search for new approaches capable of reduc-
ing the effects of the oxidative stress caused by the doxo-
rubicin is essential for clinical medicine.
It is known that ROS are also involved in the mechanisms 
of anticancer activity of cisplatin, however, their impact 
is much weaker compared to the effect of doxorubicin 
(1). p53/ROS/p38α MAPK cascade was shown to be es-
sential for cisplatin-induced cell death in HCT-116 cells 
(23). However, in our experiments antioxidants caused 
only a statistically insignificant decrease (7%) of cisplatin-
induced anticancer action toward this cell line. We found 
that ROS scavengers did not affect the consequences of 
cisplatin treatment. Thus, their application together with 
cisplatin in chemotherapy regimens does not seem to be 
effective. In contrast, sodium selenite, selenomethionine, 
and D-pantethine significantly modulated cytotoxic ac-
tivity of doxorubicin, thus, we studied doxorubicin action 
in more detail.
Although sodium selenite, selenomethionine, and D-pan-
tethine possessed similar ROS scavenging activity both in 
vitro and in vivo, the molecular mechanisms of their ac-
tion was different. We showed that all applied antioxidants 
modulated the effect of doxorubicin toward human colon 
carcinoma cells of HCT-116 line and human T-leukemia 
cells of Jurkat line via inhibiting cytotoxic activity of this 
drug by 15%-30%. It should be noted that a slight increase 
in sodium selenite and selenomethionine concentration 
from 0.1 µM to 0.25 µM (both were not toxic to target cells) 
significantly suppressed their cytoprotective effects, while 
higher doses of these compounds (5 µM, still low toxicity 
toward tumor cells in vitro) had an opposite effect, notably 
increasing doxorubicin toxicity (data not shown). Similar 
results – cytoprotective activity at low doses and enhance-
ment of cytotoxic action at higher doses – were also ob-
served for D-pantethine effect. To summarize, these results 
suggest an existence of different mechanisms of action of 
the studied antioxidants toward tumor cells depending on 
the concentration of these agents.
After finding that selenium-containing compounds par-
tially decreased cytotoxic action of doxorubicin, but not 
that of cisplatin, toward tumor cell lines with different drug 
sensitivity, it was reasonable to study in more detail antioxi-
dant modulation of the sensitivity of tumor cells with the 
MDR phenotype to doxorubicin and cisplatin.
Resistance acquisition of tumor cells to anticancer drugs 
is a serious problem in clinical practice. It was found that 
during one year of chemotherapy, resistance to anticancer 
FiGuRe 7. Selenomethionine and d-pantethine restore 
content of coenzyme A-SH (A) and acetyl-coenzyme A (B) in 
the liver of normal rats after administration of doxorubicin. 
*P < 0.05 relative to doxorubicin.
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drugs develops in 30%-50% of cancer patients (24). Drug 
resistance is a multi-factorial and complex phenomenon 
(25), which results in a significant decrease in drug accu-
mulation in cells by limiting their uptake, enhancing efflux, 
or affecting membrane lipids such as ceramide (26). These 
changes lead to: 1) inhibition of the programmed cell 
death (apoptosis) that is induced by most anticancer drugs 
(27); 2) activation of the mechanisms of general response 
that detoxify drugs and repair DNA damage (28); 3) altera-
tions in cell cycle and its checkpoints that render cancer 
cells relatively resistant to cytotoxic effects of drugs. High 
expression of P-glycoprotein, MRP-1 protein, and bcrp in 
human tumors is considered to be the first sign of negative 
prognosis for cancer patients (10). Another mechanism of 
development of drug resistance is related to genetic de-
fects in the structure of Bax and p53 genes, whose prod-
ucts play an important role in the regulation of cell cycle 
and apoptosis (29). Tumor cells with defects in these genes 
exhibit higher invasive potential, increased ability to me-
tastasize, and are more resistant to chemotherapy (30).
Combined action of anticancer drug with sodium selenite, 
selenomethionine, and D-pantethine showed a cytopro-
tective activity toward tumor cell lines that are sensitive to 
the action of doxorubicin and a reverse effect (enhancing 
of cytotoxic activity of the doxorubicin) toward drug-resis-
tant tumor cells with various defects (overexpression of P-
glycoprotein or p53 and Bax knockouts). The dual activity 
of these antioxidants can be very important in clinical prac-
tice, since using these compounds as part of cancer che-
motherapy regimens could reduce negative side effects of 
anticancer drugs toward normal cells and strengthen drug 
action in drug-resistant tumor cells.
Finally, we wanted to confirm our findings regarding cy-
toprotective effect of the selected antioxidants toward 
cultured mammalian cells treated with anticancer drugs 
in the in vivo experiments on rats treated with highly tox-
ic doxorubicin combined with the physiological doses of 
selenomethionine and D-pantethine. In our studies, anti-
oxidants and doxorubicin doses were selected on the ba-
sis of literature data (1). 1000 μg dose of L-selenomethio-
nine/kg bw/d (equivalent to 400 μg selenium/kg bw/d) 
was reported to be a no-observed-adverse-level (NOAEL) 
in a 13-week study in rats (1). At the same time, no geno-
toxicity and no carcinogenicity has been observed for D-
pantethine action, and no developmental toxicity in mice 
and rats at up to 600 mg/kg bw/d doses (31). 16 mg/kg of 
i.p. injected doxorubicin was its LD
50 dose in rats (http://
www.lclabs.com/MSDS/D-4000MSDS.php4). In the in vivo 
experiments, a cumulative dose of 1 mg/kg selenomethio-
nine (5 daily gavages of 200 µg/kg), 2000 mg/kg dose of 
D-pantethine (5 daily gavages of 400 mg/kg), and 5 mg/
kg dose of doxorubicin injected i.p. were used. 1:5 ratio for 
selenomethionine-doxorubicin and 1:400 ratio for doxo-
rubicin-D-pantethine were applied. One can see that the 
used selenomethionine and D-pantethine doses are lower 
than the corresponding NOAEL doses, while the doxorubi-
cin dose was 3 times lower than its LD50 in rats. Thus, no ad-
verse effects of selenomethionine and D-pantethine alone 
were expected.
0.05-0.25 µM range of selenomethionine dose (depend-
ing on cell line sensitivity), 1-50 µM range of D-pan-
tethine, and 0.5-5 µM dose of doxorubicin were ap-
plied in the in vitro experiments. Average ratio was 
1:5 for selenomethionine:doxorubicin and 1:100  for 
doxorubicin:D-pantethine. Thus, the same ratio of sele-
nomethionine and doxorubicin doses was applied in both 
in vitro and in vivo experiments in order to ensure the rep-
licability of the obtained results. A 400:1 ratio of D-pan-
tethine (2000 mg/kg) to doxorubicin (5 mg/kg) in the in 
vivo experiments was 4 times higher compared to the 
100:1 ratio in vitro (50 µM of D-pantethine to 0.5 µM doxo-
rubicin) due to non-toxicity of D-pantethine in mice.
The results of our in vivo studies in rats confirmed the re-
sults of in vitro studies on ROS-scavenging activity of so-
dium selenite and D-pantethine. Both these compounds 
blocked the induction of the oxidative stress in vivo. This 
was revealed by testing the restoration of redox-poten-
tial of erythrocytes and oxidative status of human plasma, 
which were increased under doxorubicin action. Besides, 
CoA level was restored in the liver of the experimental ani-
mals treated with doxorubicin. Selenomethionine did not 
have a statistically significant effect on the activity of SDH 
involved in Complex II of the mitochondrial respiratory 
chain of the liver, while D-pantethine strongly impacted 
the activity of that enzyme. This suggests various molecu-
lar mechanisms underlying cytoprotective activity of sele-
nium derivatives and D-pantethine.
In conclusion, the obtained results suggest a high poten-
tial of using selenomethionine and D-pantethine in tumor 
chemotherapy regimens in combination with a very tox-
ic drug – doxorubicin. A protective effect of the antioxi-
dant agents during cytotoxic action of doxorubicin was 
demonstrated in vitro (cultured tumor cells) and in vivo 
(laboratory rats). In case of cisplatin, such effect was 
not pronounced. These results might be important 
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for planning further pre-clinical trials of the combinatory 
treatment schemes using anticancer drugs and specific 
antioxidant compounds.
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